BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gomez-Zepeda D, Taghi M, Scherrmann JM, Decleves X, Menet MC. ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. Pharmaceutics 2019;12:E20. [PMID: 31878061 DOI: 10.3390/pharmaceutics12010020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhi K, Raji B, Nookala AR, Khan MM, Nguyen XH, Sakshi S, Pourmotabbed T, Yallapu MM, Kochat H, Tadrous E, Pernell S, Kumar S. PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP. Pharmaceutics 2021;13:500. [PMID: 33917577 DOI: 10.3390/pharmaceutics13040500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Jusko WJ, Molins EAG, Ayyar VS. Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound. Drug Metab Dispos 2020;48:894-902. [PMID: 32759367 DOI: 10.1124/dmd.120.000118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Llaguno-Munive M, Vazquez-Lopez MI, Jurado R, Garcia-Lopez P. Mifepristone Repurposing in Treatment of High-Grade Gliomas. Front Oncol 2021;11:606907. [PMID: 33680961 DOI: 10.3389/fonc.2021.606907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pifferi F, Laurent B, Plourde M. Lipid Transport and Metabolism at the Blood-Brain Interface: Implications in Health and Disease. Front Physiol 2021;12:645646. [PMID: 33868013 DOI: 10.3389/fphys.2021.645646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Catarina Duarte A, Raquel Costa A, Gonçalves I, Quintela T, Preissner R, R A Santos C. The druggability of bitter taste receptors for the treatment of neurodegenerative disorders. Biochem Pharmacol 2022;:114915. [PMID: 35051386 DOI: 10.1016/j.bcp.2022.114915] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Omidi Y, Kianinejad N, Kwon Y, Omidian H. Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier. Expert Rev Clin Pharmacol 2021;14:357-81. [PMID: 33554678 DOI: 10.1080/17512433.2021.1887729] [Reference Citation Analysis]
7 Menaceur C, Gosselet F, Fenart L, Saint-Pol J. The Blood-Brain Barrier, an Evolving Concept Based on Technological Advances and Cell-Cell Communications. Cells 2021;11:133. [PMID: 35011695 DOI: 10.3390/cells11010133] [Reference Citation Analysis]
8 Kou L, Yao Q, Zhang H, Chu M, Bhutia YD, Chen R, Ganapathy V. Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery. Cancers (Basel) 2020;12:E2837. [PMID: 33019627 DOI: 10.3390/cancers12102837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Bryniarski MA, Ren T, Rizvi AR, Snyder AM, Morris ME. Targeting the Choroid Plexuses for Protein Drug Delivery. Pharmaceutics 2020;12:E963. [PMID: 33066423 DOI: 10.3390/pharmaceutics12100963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Casati G, Giunti L, Iorio AL, Marturano A, Galli L, Sardi I. Hippo Pathway in Regulating Drug Resistance of Glioblastoma. IJMS 2021;22:13431. [DOI: 10.3390/ijms222413431] [Reference Citation Analysis]
11 Teleanu RI, Preda MD, Niculescu A, Vladâcenco O, Radu CI, Grumezescu AM, Teleanu DM. Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier. Pharmaceutics 2022;14:987. [DOI: 10.3390/pharmaceutics14050987] [Reference Citation Analysis]
12 García-Salvador A, Domínguez-Monedero A, Gómez-Fernández P, García-Bilbao A, Carregal-Romero S, Castilla J, Goñi-de-Cerio F. Evaluation of the Influence of Astrocytes on In Vitro Blood-Brain Barrier Models. Altern Lab Anim 2020;48:184-200. [PMID: 33136430 DOI: 10.1177/0261192920966954] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kassubek R, Müller HP, Thiele A, Kassubek J, Niessen HG. Advanced magnetic resonance imaging to support clinical drug development for malignant glioma. Drug Discov Today 2021;26:429-41. [PMID: 33249294 DOI: 10.1016/j.drudis.2020.11.023] [Reference Citation Analysis]
14 Manley PW, Huth F, Moussaoui S, Schoepfer J. A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood–brain barrier. Bioorganic & Medicinal Chemistry Letters 2022;59:128577. [DOI: 10.1016/j.bmcl.2022.128577] [Reference Citation Analysis]
15 Koehn LM, Huang Y, Habgood MD, Nie S, Chiou SY, Banati RB, Dziegielewska KM, Saunders NR. Efflux transporters in rat placenta and developing brain: transcriptomic and functional response to paracetamol. Sci Rep 2021;11:19878. [PMID: 34615937 DOI: 10.1038/s41598-021-99139-6] [Reference Citation Analysis]
16 Kell DB. The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes. Molecules 2021;26:5629. [PMID: 34577099 DOI: 10.3390/molecules26185629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Jena LN, Bennie LA, McErlean EM, Pentlavalli S, Glass K, Burrows JF, Kett VL, Buckley NE, Coulter JA, Dunne NJ, McCarthy HO. Exploiting the anticancer effects of a nitrogen bisphosphonate nanomedicine for glioblastoma multiforme. J Nanobiotechnology 2021;19:127. [PMID: 33947409 DOI: 10.1186/s12951-021-00856-x] [Reference Citation Analysis]
18 Karthika C, Appu AP, Akter R, Rahman MH, Tagde P, Ashraf GM, Abdel-Daim MM, Hassan SSU, Abid A, Bungau S. Potential innovation against Alzheimer's disorder: a tricomponent combination of natural antioxidants (vitamin E, quercetin, and basil oil) and the development of its intranasal delivery. Environ Sci Pollut Res Int 2022;29:10950-65. [PMID: 35000160 DOI: 10.1007/s11356-021-17830-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
19 Deligne C, Hachani J, Duban-Deweer S, Meignan S, Leblond P, Carcaboso AM, Sano Y, Shimizu F, Kanda T, Gosselet F, Dehouck MP, Mysiorek C. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS 2020;17:37. [PMID: 32487241 DOI: 10.1186/s12987-020-00198-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
20 Khadka B, Lee JY, Park EK, Kim KT, Bae JS. Impacts of Drug Interactions on Pharmacokinetics and the Brain Transporters: A Recent Review of Natural Compound-Drug Interactions in Brain Disorders. Int J Mol Sci 2021;22:1809. [PMID: 33670407 DOI: 10.3390/ijms22041809] [Reference Citation Analysis]
21 Cai P, Zheng Y, Sun Y, Zhang C, Zhang Q, Liu Q. New Blood-Brain Barrier Models Using Primary Parkinson's Disease Rat Brain Endothelial Cells and Astrocytes for the Development of Central Nervous System Drug Delivery Systems. ACS Chem Neurosci 2021;12:3829-37. [PMID: 34623131 DOI: 10.1021/acschemneuro.1c00118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Nicklisch SCT, Hamdoun A. Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs). FEBS Lett 2020;594:4158-85. [PMID: 33222203 DOI: 10.1002/1873-3468.14005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res 2021;171:105780. [PMID: 34302977 DOI: 10.1016/j.phrs.2021.105780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Tian ZR, Sahib S, Bryukhovetskiy I, Bryukhovetskiy A, Buzoianu AD, Patnaik R, Wiklund L, Sharma A. Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine. Int Rev Neurobiol 2020;151:1-66. [PMID: 32448602 DOI: 10.1016/bs.irn.2020.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
25 Zhang S, Peng X, Li X, Liu H, Zhao B, Elkabets M, Liu Y, Wang W, Wang R, Zhong Y, Kong D. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death Dis 2021;12:546. [PMID: 34039959 DOI: 10.1038/s41419-021-03805-6] [Reference Citation Analysis]